| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | peptide lactyltransferase (CoA-dependent) activity | 1.63e-06 | 2 | 26 | 2 | GO:0120300 | |
| GeneOntologyMolecularFunction | histone H3K27 acetyltransferase activity | 1.63e-06 | 2 | 26 | 2 | GO:0044017 | |
| GeneOntologyMolecularFunction | histone H3K18 acetyltransferase activity | 4.89e-06 | 3 | 26 | 2 | GO:0043993 | |
| GeneOntologyMolecularFunction | transcription coactivator activity | 3.94e-05 | 303 | 26 | 5 | GO:0003713 | |
| GeneOntologyMolecularFunction | transcription coregulator activity | 6.89e-05 | 562 | 26 | 6 | GO:0003712 | |
| GeneOntologyMolecularFunction | histone H3 acetyltransferase activity | 1.69e-04 | 15 | 26 | 2 | GO:0010484 | |
| GeneOntologyMolecularFunction | histone modifying activity | 2.07e-04 | 229 | 26 | 4 | GO:0140993 | |
| GeneOntologyMolecularFunction | N-acyltransferase activity | 3.09e-04 | 102 | 26 | 3 | GO:0016410 | |
| GeneOntologyMolecularFunction | peroxisome proliferator activated receptor binding | 3.37e-04 | 21 | 26 | 2 | GO:0042975 | |
| GeneOntologyMolecularFunction | beta-catenin binding | 4.97e-04 | 120 | 26 | 3 | GO:0008013 | |
| GeneOntologyMolecularFunction | bHLH transcription factor binding | 1.06e-03 | 37 | 26 | 2 | GO:0043425 | |
| GeneOntologyMolecularFunction | molecular adaptor activity | 1.37e-03 | 1356 | 26 | 7 | GO:0060090 | |
| GeneOntologyMolecularFunction | histone H3 methyltransferase activity | 1.49e-03 | 44 | 26 | 2 | GO:0140938 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 1.95e-03 | 417 | 26 | 4 | GO:0061629 | |
| GeneOntologyMolecularFunction | histone acetyltransferase activity | 2.00e-03 | 51 | 26 | 2 | GO:0004402 | |
| GeneOntologyMolecularFunction | transcription coactivator binding | 2.24e-03 | 54 | 26 | 2 | GO:0001223 | |
| GeneOntologyMolecularFunction | peptide-lysine-N-acetyltransferase activity | 2.32e-03 | 55 | 26 | 2 | GO:0061733 | |
| GeneOntologyMolecularFunction | peptide N-acetyltransferase activity | 2.75e-03 | 60 | 26 | 2 | GO:0034212 | |
| GeneOntologyMolecularFunction | acyltransferase activity | 2.90e-03 | 775 | 26 | 5 | GO:0016746 | |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | 3.20e-03 | 1160 | 26 | 6 | GO:0030674 | |
| GeneOntologyMolecularFunction | protein-lysine N-methyltransferase activity | 3.52e-03 | 68 | 26 | 2 | GO:0016279 | |
| GeneOntologyMolecularFunction | acyltransferase activity, transferring groups other than amino-acyl groups | 3.55e-03 | 238 | 26 | 3 | GO:0016747 | |
| GeneOntologyMolecularFunction | lysine N-methyltransferase activity | 3.63e-03 | 69 | 26 | 2 | GO:0016278 | |
| GeneOntologyMolecularFunction | histone methyltransferase activity | 3.83e-03 | 71 | 26 | 2 | GO:0042054 | |
| GeneOntologyMolecularFunction | p53 binding | 4.49e-03 | 77 | 26 | 2 | GO:0002039 | |
| GeneOntologyMolecularFunction | N-acetyltransferase activity | 4.61e-03 | 78 | 26 | 2 | GO:0008080 | |
| GeneOntologyMolecularFunction | damaged DNA binding | 5.32e-03 | 84 | 26 | 2 | GO:0003684 | |
| GeneOntologyMolecularFunction | SMAD binding | 5.57e-03 | 86 | 26 | 2 | GO:0046332 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor binding | 6.41e-03 | 582 | 26 | 4 | GO:0140297 | |
| GeneOntologyMolecularFunction | protein methyltransferase activity | 7.90e-03 | 103 | 26 | 2 | GO:0008276 | |
| GeneOntologyMolecularFunction | acetyltransferase activity | 8.05e-03 | 104 | 26 | 2 | GO:0016407 | |
| GeneOntologyMolecularFunction | N-methyltransferase activity | 8.20e-03 | 105 | 26 | 2 | GO:0008170 | |
| GeneOntologyMolecularFunction | transcription coregulator binding | 1.42e-02 | 140 | 26 | 2 | GO:0001221 | |
| GeneOntologyBiologicalProcess | N-terminal peptidyl-lysine acetylation | 9.15e-06 | 4 | 26 | 2 | GO:0018076 | |
| GeneOntologyBiologicalProcess | stem cell population maintenance | 1.04e-05 | 237 | 26 | 5 | GO:0019827 | |
| GeneOntologyBiologicalProcess | maintenance of cell number | 1.15e-05 | 242 | 26 | 5 | GO:0098727 | |
| GeneOntologyBiologicalProcess | regulation of transforming growth factor beta receptor signaling pathway | 9.27e-05 | 192 | 26 | 4 | GO:0017015 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to transforming growth factor beta stimulus | 9.84e-05 | 195 | 26 | 4 | GO:1903844 | |
| GeneOntologyBiologicalProcess | cell junction organization | 1.53e-04 | 974 | 26 | 7 | GO:0034330 | |
| GeneOntologyBiologicalProcess | N-terminal protein amino acid acetylation | 1.81e-04 | 16 | 26 | 2 | GO:0006474 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to heat | 1.81e-04 | 16 | 26 | 2 | GO:1900034 | |
| GeneOntologyBiologicalProcess | somatic stem cell population maintenance | 3.32e-04 | 108 | 26 | 3 | GO:0035019 | |
| GeneOntologyBiologicalProcess | transforming growth factor beta receptor signaling pathway | 3.72e-04 | 276 | 26 | 4 | GO:0007179 | |
| GeneOntologyBiologicalProcess | stimulatory C-type lectin receptor signaling pathway | 3.80e-04 | 23 | 26 | 2 | GO:0002223 | |
| GeneOntologyBiologicalProcess | cellular response to lectin | 3.80e-04 | 23 | 26 | 2 | GO:1990858 | |
| GeneOntologyBiologicalProcess | response to lectin | 3.80e-04 | 23 | 26 | 2 | GO:1990840 | |
| GeneOntologyBiologicalProcess | peptidyl-lysine acetylation | 5.66e-04 | 28 | 26 | 2 | GO:0018394 | |
| GeneOntologyBiologicalProcess | N-terminal protein amino acid modification | 6.07e-04 | 29 | 26 | 2 | GO:0031365 | |
| GeneOntologyBiologicalProcess | cell junction assembly | 6.39e-04 | 569 | 26 | 5 | GO:0034329 | |
| GeneOntologyBiologicalProcess | positive regulation of cell junction assembly | 6.52e-04 | 136 | 26 | 3 | GO:1901890 | |
| GeneOntologyBiologicalProcess | myoblast differentiation | 6.52e-04 | 136 | 26 | 3 | GO:0045445 | |
| GeneOntologyBiologicalProcess | cellular response to transforming growth factor beta stimulus | 7.79e-04 | 336 | 26 | 4 | GO:0071560 | |
| GeneOntologyBiologicalProcess | negative regulation of miRNA metabolic process | 8.36e-04 | 34 | 26 | 2 | GO:2000629 | |
| GeneOntologyBiologicalProcess | postsynaptic density assembly | 8.36e-04 | 34 | 26 | 2 | GO:0097107 | |
| GeneOntologyBiologicalProcess | response to transforming growth factor beta | 8.41e-04 | 343 | 26 | 4 | GO:0071559 | |
| GeneOntologyBiologicalProcess | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 8.78e-04 | 347 | 26 | 4 | GO:0090092 | |
| GeneOntologyBiologicalProcess | positive regulation of cellular response to transforming growth factor beta stimulus | 8.86e-04 | 35 | 26 | 2 | GO:1903846 | |
| GeneOntologyBiologicalProcess | positive regulation of transforming growth factor beta receptor signaling pathway | 8.86e-04 | 35 | 26 | 2 | GO:0030511 | |
| GeneOntologyBiologicalProcess | peptidyl-lysine modification | 1.08e-03 | 162 | 26 | 3 | GO:0018205 | |
| GeneOntologyBiologicalProcess | nuclear transport | 1.21e-03 | 378 | 26 | 4 | GO:0051169 | |
| GeneOntologyBiologicalProcess | nucleocytoplasmic transport | 1.21e-03 | 378 | 26 | 4 | GO:0006913 | |
| GeneOntologyBiologicalProcess | face morphogenesis | 1.22e-03 | 41 | 26 | 2 | GO:0060325 | |
| GeneOntologyBiologicalProcess | protein-DNA complex organization | 1.27e-03 | 999 | 26 | 6 | GO:0071824 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | 1.31e-03 | 1390 | 26 | 7 | GO:0045944 | |
| GeneOntologyBiologicalProcess | postsynaptic specialization assembly | 1.40e-03 | 44 | 26 | 2 | GO:0098698 | |
| GeneOntologyBiologicalProcess | synapse organization | 1.47e-03 | 685 | 26 | 5 | GO:0050808 | |
| GeneOntologyBiologicalProcess | excitatory synapse assembly | 1.53e-03 | 46 | 26 | 2 | GO:1904861 | |
| GeneOntologyBiologicalProcess | response to organic cyclic compound | 1.63e-03 | 1048 | 26 | 6 | GO:0014070 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to growth factor stimulus | 1.66e-03 | 412 | 26 | 4 | GO:0090287 | |
| GeneOntologyBiologicalProcess | head morphogenesis | 1.66e-03 | 48 | 26 | 2 | GO:0060323 | |
| GeneOntologyBiologicalProcess | neurotransmitter receptor localization to postsynaptic specialization membrane | 1.73e-03 | 49 | 26 | 2 | GO:0099645 | |
| GeneOntologyBiologicalProcess | protein localization to postsynaptic specialization membrane | 1.73e-03 | 49 | 26 | 2 | GO:0099633 | |
| GeneOntologyCellularComponent | transcription regulator complex | 7.41e-05 | 596 | 26 | 6 | GO:0005667 | |
| GeneOntologyCellularComponent | beta-catenin-TCF complex | 1.15e-04 | 13 | 26 | 2 | GO:1990907 | |
| GeneOntologyCellularComponent | RNA polymerase II transcription regulator complex | 3.35e-04 | 272 | 26 | 4 | GO:0090575 | |
| GeneOntologyCellularComponent | Schaffer collateral - CA1 synapse | 9.17e-04 | 155 | 26 | 3 | GO:0098685 | |
| HumanPheno | Square face | 2.11e-06 | 16 | 9 | 3 | HP:0000321 | |
| HumanPheno | Aortic isthmus hypoplasia | 2.78e-06 | 2 | 9 | 2 | HP:0034227 | |
| HumanPheno | Plantar crease between first and second toes | 2.78e-06 | 2 | 9 | 2 | HP:0008107 | |
| HumanPheno | High axial triradius | 2.78e-06 | 2 | 9 | 2 | HP:0001042 | |
| HumanPheno | Humoral immunodeficiency | 8.32e-06 | 3 | 9 | 2 | HP:0005363 | |
| HumanPheno | Prominent nasal septum | 8.32e-06 | 3 | 9 | 2 | HP:0005322 | |
| HumanPheno | Radial deviation of thumb terminal phalanx | 8.32e-06 | 3 | 9 | 2 | HP:0005895 | |
| HumanPheno | Laryngeal cartilage malformation | 8.32e-06 | 3 | 9 | 2 | HP:0008752 | |
| HumanPheno | Phobia | 8.32e-06 | 3 | 9 | 2 | HP:5200232 | |
| HumanPheno | Agoraphobia | 8.32e-06 | 3 | 9 | 2 | HP:0000756 | |
| HumanPheno | Trichiasis | 1.66e-05 | 4 | 9 | 2 | HP:0001128 | |
| HumanPheno | Widened distal phalanges | 1.66e-05 | 4 | 9 | 2 | HP:0006200 | |
| HumanPheno | Visceral hemangioma | 1.66e-05 | 4 | 9 | 2 | HP:0410266 | |
| HumanPheno | Talon cusp | 1.66e-05 | 4 | 9 | 2 | HP:0011087 | |
| HumanPheno | Vascular ring | 1.66e-05 | 4 | 9 | 2 | HP:0010775 | |
| HumanPheno | Hepatic hemangioma | 1.66e-05 | 4 | 9 | 2 | HP:0031207 | |
| HumanPheno | Syringomyelia | 2.03e-05 | 33 | 9 | 3 | HP:0003396 | |
| HumanPheno | Abnormality of the distal phalanx of the thumb | 2.65e-05 | 36 | 9 | 3 | HP:0009617 | |
| HumanPheno | Papillary cystadenoma of the epididymis | 2.77e-05 | 5 | 9 | 2 | HP:0009715 | |
| HumanPheno | Supernumerary cusp | 2.77e-05 | 5 | 9 | 2 | HP:0033777 | |
| HumanPheno | Epididymal neoplasm | 2.77e-05 | 5 | 9 | 2 | HP:0030421 | |
| HumanPheno | Auditory sensitivity | 2.88e-05 | 37 | 9 | 3 | HP:0025112 | |
| HumanPheno | Auditory hypersensitivity | 2.88e-05 | 37 | 9 | 3 | HP:5200060 | |
| HumanPheno | Natal tooth | 3.12e-05 | 38 | 9 | 3 | HP:0000695 | |
| HumanPheno | Large foramen magnum | 4.15e-05 | 6 | 9 | 2 | HP:0002700 | |
| HumanPheno | Spinal cord lesion | 5.57e-05 | 46 | 9 | 3 | HP:0100561 | |
| HumanPheno | Advanced eruption of teeth | 5.57e-05 | 46 | 9 | 3 | HP:0006288 | |
| HumanPheno | Deviated nasal septum | 5.80e-05 | 7 | 9 | 2 | HP:0004411 | |
| HumanPheno | Chiari type I malformation | 6.34e-05 | 48 | 9 | 3 | HP:0007099 | |
| HumanPheno | Pilomatrixoma | 9.93e-05 | 9 | 9 | 2 | HP:0030434 | |
| HumanPheno | Cervical cord compression | 9.93e-05 | 9 | 9 | 2 | HP:0002341 | |
| HumanPheno | Low hanging columella | 1.01e-04 | 56 | 9 | 3 | HP:0009765 | |
| HumanPheno | Frontal hirsutism | 1.24e-04 | 10 | 9 | 2 | HP:0011335 | |
| HumanPheno | Sleep apnea | 1.26e-04 | 168 | 9 | 4 | HP:0010535 | |
| HumanPheno | Sleep-related breathing disorders | 1.29e-04 | 169 | 9 | 4 | HP:5200283 | |
| HumanPheno | Abnormal subclavian artery morphology | 1.51e-04 | 11 | 9 | 2 | HP:0031251 | |
| HumanPheno | Precocious puberty | 1.88e-04 | 186 | 9 | 4 | HP:0000826 | |
| HumanPheno | Early onset of sexual maturation | 2.00e-04 | 189 | 9 | 4 | HP:0100000 | |
| HumanPheno | Conductive hearing impairment | 2.02e-04 | 373 | 9 | 5 | HP:0000405 | |
| HumanPheno | Facial grimacing | 2.14e-04 | 13 | 9 | 2 | HP:0000273 | |
| HumanPheno | Keloids | 2.14e-04 | 13 | 9 | 2 | HP:0010562 | |
| HumanPheno | Functional abnormality of the middle ear | 2.38e-04 | 386 | 9 | 5 | HP:0011452 | |
| HumanPheno | Parietal foramina | 2.50e-04 | 14 | 9 | 2 | HP:0002697 | |
| HumanPheno | Duplication of phalanx of hallux | 2.50e-04 | 14 | 9 | 2 | HP:0010066 | |
| HumanPheno | Hypoplastic aortic arch | 2.50e-04 | 14 | 9 | 2 | HP:0012304 | |
| HumanPheno | Social and occupational deterioration | 2.88e-04 | 15 | 9 | 2 | HP:0007086 | |
| HumanPheno | Duplication of phalanx of toe | 2.88e-04 | 15 | 9 | 2 | HP:0010181 | |
| HumanPheno | Self-injurious behavior | 3.00e-04 | 210 | 9 | 4 | HP:0100716 | |
| HumanPheno | Supernumerary tooth | 3.50e-04 | 85 | 9 | 3 | HP:0011069 | |
| HumanPheno | Premature thelarche | 3.72e-04 | 17 | 9 | 2 | HP:0010314 | |
| HumanPheno | Tall stature | 3.92e-04 | 225 | 9 | 4 | HP:0000098 | |
| HumanPheno | Abnormal midface morphology | 3.95e-04 | 704 | 9 | 6 | HP:0000309 | |
| HumanPheno | Facial hirsutism | 4.18e-04 | 18 | 9 | 2 | HP:0009937 | |
| HumanPheno | Skin appendage neoplasm | 4.18e-04 | 18 | 9 | 2 | HP:0012842 | |
| HumanPheno | Abnormality of dental eruption | 5.02e-04 | 240 | 9 | 4 | HP:0006292 | |
| HumanPheno | Abnormal columella morphology | 5.17e-04 | 97 | 9 | 3 | HP:0009929 | |
| HumanPheno | Absent earlobe | 5.19e-04 | 20 | 9 | 2 | HP:0000387 | |
| HumanPheno | Localized hirsutism | 5.73e-04 | 21 | 9 | 2 | HP:0009889 | |
| HumanPheno | Deep plantar creases | 5.73e-04 | 21 | 9 | 2 | HP:0001869 | |
| HumanPheno | Corneal scarring | 5.73e-04 | 21 | 9 | 2 | HP:0000559 | |
| HumanPheno | Enamel hypoplasia | 6.35e-04 | 104 | 9 | 3 | HP:0006297 | |
| HumanPheno | Aplasia/Hypoplasia of the corpus callosum | 6.62e-04 | 772 | 9 | 6 | HP:0007370 | |
| HumanPheno | Abnormal foramen magnum morphology | 6.89e-04 | 23 | 9 | 2 | HP:0002699 | |
| HumanPheno | Agenesis of permanent teeth | 6.89e-04 | 23 | 9 | 2 | HP:0006349 | |
| HumanPheno | Chiari malformation | 6.90e-04 | 107 | 9 | 3 | HP:0002308 | |
| HumanPheno | Abnormality of the incisor | 7.09e-04 | 108 | 9 | 3 | HP:0000676 | |
| HumanPheno | Autism | 7.23e-04 | 264 | 9 | 4 | HP:0000717 | |
| HumanPheno | Increased body weight | 7.39e-04 | 491 | 9 | 5 | HP:0004324 | |
| HumanPheno | Simple ear | 7.51e-04 | 24 | 9 | 2 | HP:0020206 | |
| HumanPheno | Broad hallux phalanx | 7.51e-04 | 24 | 9 | 2 | HP:0010059 | |
| HumanPheno | Shawl scrotum | 8.15e-04 | 25 | 9 | 2 | HP:0000049 | |
| HumanPheno | Abnormal nasal septum morphology | 8.53e-04 | 115 | 9 | 3 | HP:0000419 | |
| HumanPheno | Minor feet anomalies | 8.82e-04 | 26 | 9 | 2 | HP:0010613 | |
| HumanPheno | Abnormal feet morphology | 8.82e-04 | 26 | 9 | 2 | HP:0010611 | |
| HumanPheno | Phonophobia | 8.82e-04 | 26 | 9 | 2 | HP:0002183 | |
| HumanPheno | Perimembranous ventricular septal defect | 8.82e-04 | 26 | 9 | 2 | HP:0011682 | |
| HumanPheno | Aggressive behavior | 9.32e-04 | 516 | 9 | 5 | HP:0000718 | |
| HumanPheno | Abnormal aggressive, impulsive or violent behavior | 9.32e-04 | 516 | 9 | 5 | HP:0006919 | |
| HumanPheno | Flared iliac wing | 9.52e-04 | 27 | 9 | 2 | HP:0002869 | |
| HumanPheno | Broad distal phalanx of finger | 9.52e-04 | 27 | 9 | 2 | HP:0009836 | |
| HumanPheno | Hypermetropia | 1.01e-03 | 288 | 9 | 4 | HP:0000540 | |
| HumanPheno | Short palpebral fissure | 1.01e-03 | 122 | 9 | 3 | HP:0012745 | |
| HumanPheno | Short columella | 1.10e-03 | 29 | 9 | 2 | HP:0002000 | |
| HumanPheno | Abnormal parietal bone morphology | 1.10e-03 | 29 | 9 | 2 | HP:0002696 | |
| HumanPheno | Broad eyebrow | 1.10e-03 | 29 | 9 | 2 | HP:0011229 | |
| HumanPheno | Hypoplasia of teeth | 1.11e-03 | 126 | 9 | 3 | HP:0000685 | |
| HumanPheno | Abnormal dental morphology | 1.16e-03 | 299 | 9 | 4 | HP:0006482 | |
| HumanPheno | Avascular necrosis of the capital femoral epiphysis | 1.18e-03 | 30 | 9 | 2 | HP:0005743 | |
| HumanPheno | Abnormal epididymis morphology | 1.18e-03 | 30 | 9 | 2 | HP:0009714 | |
| HumanPheno | Preaxial foot polydactyly | 1.18e-03 | 30 | 9 | 2 | HP:0001841 | |
| HumanPheno | Hypoplasia of the maxilla | 1.22e-03 | 130 | 9 | 3 | HP:0000327 | |
| HumanPheno | Hypoplastic iliac wing | 1.26e-03 | 31 | 9 | 2 | HP:0002866 | |
| HumanPheno | Thin corpus callosum | 1.27e-03 | 868 | 9 | 6 | HP:0033725 | |
| HumanPheno | Abnormal pattern of respiration | 1.30e-03 | 872 | 9 | 6 | HP:0002793 | |
| HumanPheno | Aplasia/Hypoplasia of the maxilla | 1.30e-03 | 133 | 9 | 3 | HP:0009117 | |
| HumanPheno | Abnormal earlobe morphology | 1.42e-03 | 137 | 9 | 3 | HP:0000363 | |
| HumanPheno | Frontal upsweep of hair | 1.42e-03 | 33 | 9 | 2 | HP:0002236 | |
| HumanPheno | Abnormal branching pattern of the aortic arch | 1.42e-03 | 33 | 9 | 2 | HP:0011587 | |
| HumanPheno | Neoplasm of the liver | 1.51e-03 | 140 | 9 | 3 | HP:0002896 | |
| HumanPheno | Aspiration | 1.51e-03 | 34 | 9 | 2 | HP:0002835 | |
| Domain | - | 1.72e-06 | 2 | 25 | 2 | 1.10.246.20 | |
| Domain | zf-TAZ | 1.72e-06 | 2 | 25 | 2 | PF02135 | |
| Domain | ZF_TAZ | 1.72e-06 | 2 | 25 | 2 | PS50134 | |
| Domain | BCL9_beta-catenin-bd_dom | 1.72e-06 | 2 | 25 | 2 | IPR024670 | |
| Domain | Nuc_rcpt_coact_CREBbp | 1.72e-06 | 2 | 25 | 2 | IPR014744 | |
| Domain | HAT_KAT11 | 1.72e-06 | 2 | 25 | 2 | PF08214 | |
| Domain | KIX | 1.72e-06 | 2 | 25 | 2 | PS50952 | |
| Domain | BCL9 | 1.72e-06 | 2 | 25 | 2 | PF11502 | |
| Domain | ZnF_TAZ | 1.72e-06 | 2 | 25 | 2 | SM00551 | |
| Domain | CBP_P300_HAT | 1.72e-06 | 2 | 25 | 2 | IPR031162 | |
| Domain | Histone_AcTrfase_Rtt109/CBP | 1.72e-06 | 2 | 25 | 2 | IPR013178 | |
| Domain | DUF902 | 1.72e-06 | 2 | 25 | 2 | PF06001 | |
| Domain | - | 1.72e-06 | 2 | 25 | 2 | 1.20.1020.10 | |
| Domain | RING_CBP-p300 | 1.72e-06 | 2 | 25 | 2 | IPR010303 | |
| Domain | KAT11 | 1.72e-06 | 2 | 25 | 2 | SM01250 | |
| Domain | - | 1.72e-06 | 2 | 25 | 2 | 1.10.1630.10 | |
| Domain | Znf_TAZ | 1.72e-06 | 2 | 25 | 2 | IPR000197 | |
| Domain | KIX_dom | 1.72e-06 | 2 | 25 | 2 | IPR003101 | |
| Domain | Creb_binding | 1.72e-06 | 2 | 25 | 2 | PF09030 | |
| Domain | KIX | 1.72e-06 | 2 | 25 | 2 | PF02172 | |
| Domain | Bcl-9 | 1.72e-06 | 2 | 25 | 2 | IPR015668 | |
| Domain | CBP_P300_HAT | 1.72e-06 | 2 | 25 | 2 | PS51727 | |
| Domain | Nuc_rcpt_coact | 2.57e-05 | 6 | 25 | 2 | IPR009110 | |
| Domain | INT_SG_DDX_CT_C | 4.79e-05 | 8 | 25 | 2 | PF15300 | |
| Domain | INT_SG_DDX_CT_C | 4.79e-05 | 8 | 25 | 2 | IPR029307 | |
| Domain | Post-SET_dom | 2.04e-04 | 16 | 25 | 2 | IPR003616 | |
| Domain | PostSET | 2.04e-04 | 16 | 25 | 2 | SM00508 | |
| Domain | POST_SET | 2.04e-04 | 16 | 25 | 2 | PS50868 | |
| Domain | ZF_ZZ_2 | 2.60e-04 | 18 | 25 | 2 | PS50135 | |
| Domain | ZF_ZZ_1 | 2.60e-04 | 18 | 25 | 2 | PS01357 | |
| Domain | ZZ | 2.60e-04 | 18 | 25 | 2 | PF00569 | |
| Domain | Znf_ZZ | 2.90e-04 | 19 | 25 | 2 | IPR000433 | |
| Domain | ZnF_ZZ | 2.90e-04 | 19 | 25 | 2 | SM00291 | |
| Domain | Bromodomain_CS | 5.48e-04 | 26 | 25 | 2 | IPR018359 | |
| Domain | BROMODOMAIN_1 | 1.11e-03 | 37 | 25 | 2 | PS00633 | |
| Domain | Bromodomain | 1.17e-03 | 38 | 25 | 2 | PF00439 | |
| Domain | BROMODOMAIN_2 | 1.37e-03 | 41 | 25 | 2 | PS50014 | |
| Domain | SET | 1.37e-03 | 41 | 25 | 2 | PF00856 | |
| Domain | BROMO | 1.43e-03 | 42 | 25 | 2 | SM00297 | |
| Domain | Bromodomain | 1.43e-03 | 42 | 25 | 2 | IPR001487 | |
| Domain | - | 1.43e-03 | 42 | 25 | 2 | 1.20.920.10 | |
| Domain | SET | 1.72e-03 | 46 | 25 | 2 | SM00317 | |
| Domain | SET_dom | 2.03e-03 | 50 | 25 | 2 | IPR001214 | |
| Domain | SET | 2.03e-03 | 50 | 25 | 2 | PS50280 | |
| Domain | PTPc_motif | 2.81e-03 | 59 | 25 | 2 | SM00404 | |
| Domain | Tyr_Pase_cat | 2.81e-03 | 59 | 25 | 2 | IPR003595 | |
| Domain | C1 | 3.40e-03 | 65 | 25 | 2 | SM00109 | |
| Domain | PE/DAG-bd | 3.50e-03 | 66 | 25 | 2 | IPR002219 | |
| Domain | - | 6.69e-03 | 92 | 25 | 2 | 3.90.190.10 | |
| Domain | Prot-tyrosine_phosphatase-like | 7.71e-03 | 99 | 25 | 2 | IPR029021 | |
| Pathway | WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA | 1.89e-06 | 65 | 20 | 4 | M39682 | |
| Pathway | REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX | 6.22e-06 | 26 | 20 | 3 | MM14793 | |
| Pathway | REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX | 7.27e-06 | 91 | 20 | 4 | M27101 | |
| Pathway | WP_TYPE_2_PAPILLARY_RENAL_CELL_CARCINOMA | 1.42e-05 | 34 | 20 | 3 | M39771 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 1.91e-05 | 5 | 20 | 2 | MM1575 | |
| Pathway | REACTOME_NFE2L2_REGULATING_INFLAMMATION_ASSOCIATED_GENES | 1.91e-05 | 5 | 20 | 2 | M48020 | |
| Pathway | REACTOME_LRR_FLII_INTERACTING_PROTEIN_1_LRRFIP1_ACTIVATES_TYPE_I_IFN_PRODUCTION | 1.91e-05 | 5 | 20 | 2 | M27228 | |
| Pathway | REACTOME_NFE2L2_REGULATING_ER_STRESS_ASSOCIATED_GENES | 1.91e-05 | 5 | 20 | 2 | M48023 | |
| Pathway | REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA | 2.04e-05 | 118 | 20 | 4 | M27316 | |
| Pathway | REACTOME_MATERNAL_TO_ZYGOTIC_TRANSITION_MZT | 2.81e-05 | 128 | 20 | 4 | M48019 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 2.86e-05 | 6 | 20 | 2 | M22062 | |
| Pathway | REACTOME_CHROMATIN_MODIFYING_ENZYMES | 3.15e-05 | 272 | 20 | 5 | M29619 | |
| Pathway | BIOCARTA_PPARG_PATHWAY | 4.00e-05 | 7 | 20 | 2 | MM1573 | |
| Pathway | BIOCARTA_PPARG_PATHWAY | 5.33e-05 | 8 | 20 | 2 | M22058 | |
| Pathway | REACTOME_NFE2L2_REGULATING_MDR_ASSOCIATED_ENZYMES | 5.33e-05 | 8 | 20 | 2 | M48022 | |
| Pathway | REACTOME_REGULATION_OF_NFE2L2_GENE_EXPRESSION | 5.33e-05 | 8 | 20 | 2 | M48024 | |
| Pathway | REACTOME_NFE2L2_REGULATES_PENTOSE_PHOSPHATE_PATHWAY_GENES | 5.33e-05 | 8 | 20 | 2 | M46443 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR3_IRF3_SIGNALING_PATHWAY | 6.84e-05 | 9 | 20 | 2 | M47451 | |
| Pathway | REACTOME_REGULATION_OF_FOXO_TRANSCRIPTIONAL_ACTIVITY_BY_ACETYLATION | 8.55e-05 | 10 | 20 | 2 | M27945 | |
| Pathway | BIOCARTA_CARM1_PATHWAY | 1.04e-04 | 11 | 20 | 2 | MM1521 | |
| Pathway | REACTOME_NFE2L2_REGULATING_TUMORIGENIC_GENES | 1.04e-04 | 11 | 20 | 2 | M48021 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_BY_HYPOXIA_INDUCIBLE_FACTOR | 1.04e-04 | 11 | 20 | 2 | M26924 | |
| Pathway | KEGG_HUNTINGTONS_DISEASE | 1.11e-04 | 182 | 20 | 4 | M13486 | |
| Pathway | BIOCARTA_CARM1_PATHWAY | 1.25e-04 | 12 | 20 | 2 | M7968 | |
| Pathway | REACTOME_ACTIVATION_OF_THE_TFAP2_AP_2_FAMILY_OF_TRANSCRIPTION_FACTORS | 1.25e-04 | 12 | 20 | 2 | M27765 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 1.72e-04 | 14 | 20 | 2 | M27808 | |
| Pathway | BIOCARTA_RELA_PATHWAY | 1.99e-04 | 15 | 20 | 2 | MM1339 | |
| Pathway | BIOCARTA_RELA_PATHWAY | 1.99e-04 | 15 | 20 | 2 | M10183 | |
| Pathway | BIOCARTA_PITX2_PATHWAY | 1.99e-04 | 15 | 20 | 2 | MM1439 | |
| Pathway | REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY | 1.99e-04 | 15 | 20 | 2 | M953 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION | 2.16e-04 | 84 | 20 | 3 | M1008 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 2.27e-04 | 16 | 20 | 2 | M1296 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 2.27e-04 | 16 | 20 | 2 | MM1420 | |
| Pathway | BIOCARTA_PITX2_PATHWAY | 2.27e-04 | 16 | 20 | 2 | M8516 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS | 2.27e-04 | 16 | 20 | 2 | M27121 | |
| Pathway | REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_CELL_DEATH_GENES | 2.27e-04 | 16 | 20 | 2 | M27940 | |
| Pathway | WP_CLEAR_CELL_RENAL_CELL_CARCINOMA_PATHWAYS | 2.32e-04 | 86 | 20 | 3 | M39375 | |
| Pathway | BIOCARTA_TGFB_PATHWAY | 2.57e-04 | 17 | 20 | 2 | MM1509 | |
| Pathway | REACTOME_ZYGOTIC_GENOME_ACTIVATION_ZGA | 2.57e-04 | 17 | 20 | 2 | M48025 | |
| Pathway | REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT | 2.86e-04 | 233 | 20 | 4 | M27099 | |
| Pathway | REACTOME_RORA_ACTIVATES_GENE_EXPRESSION | 2.89e-04 | 18 | 20 | 2 | M26942 | |
| Pathway | BIOCARTA_TGFB_PATHWAY | 3.22e-04 | 19 | 20 | 2 | M18933 | |
| Pathway | REACTOME_NFE2L2_REGULATING_ANTI_OXIDANT_DETOXIFICATION_ENZYMES | 3.22e-04 | 19 | 20 | 2 | M46442 | |
| Pathway | REACTOME_RSV_HOST_INTERACTIONS | 3.41e-04 | 98 | 20 | 3 | M48247 | |
| Pathway | REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 3.58e-04 | 20 | 20 | 2 | M27881 | |
| Pathway | WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX | 3.95e-04 | 21 | 20 | 2 | M39593 | |
| Pathway | REACTOME_CD209_DC_SIGN_SIGNALING | 3.95e-04 | 21 | 20 | 2 | M27485 | |
| Pathway | BIOCARTA_NTHI_PATHWAY | 4.34e-04 | 22 | 20 | 2 | MM1443 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 4.34e-04 | 22 | 20 | 2 | MM1370 | |
| Pathway | BIOCARTA_NTHI_PATHWAY | 4.75e-04 | 23 | 20 | 2 | M2821 | |
| Pathway | REACTOME_ADIPOGENESIS | 4.78e-04 | 110 | 20 | 3 | M48259 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 5.18e-04 | 24 | 20 | 2 | M13404 | |
| Pathway | REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 5.63e-04 | 25 | 20 | 2 | M27880 | |
| Pathway | BIOCARTA_CARM_ER_PATHWAY | 6.09e-04 | 26 | 20 | 2 | M2499 | |
| Pathway | PID_HDAC_CLASSIII_PATHWAY | 6.09e-04 | 26 | 20 | 2 | M32 | |
| Pathway | REACTOME_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY | 6.17e-04 | 120 | 20 | 3 | M48233 | |
| Pathway | REACTOME_ACTIVATION_OF_ANTERIOR_HOX_GENES_IN_HINDBRAIN_DEVELOPMENT_DURING_EARLY_EMBRYOGENESIS | 6.47e-04 | 122 | 20 | 3 | M29689 | |
| Pathway | REACTOME_ATTENUATION_PHASE | 7.07e-04 | 28 | 20 | 2 | M27254 | |
| Pathway | PID_RETINOIC_ACID_PATHWAY | 8.12e-04 | 30 | 20 | 2 | M207 | |
| Pathway | REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION | 8.12e-04 | 30 | 20 | 2 | M936 | |
| Pathway | WP_INITIATION_OF_TRANSCRIPTION_AND_TRANSLATION_ELONGATION_AT_THE_HIV1_LTR | 9.25e-04 | 32 | 20 | 2 | M39521 | |
| Pathway | PID_HIF2PATHWAY | 1.04e-03 | 34 | 20 | 2 | M44 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_NPAS4 | 1.04e-03 | 34 | 20 | 2 | M46422 | |
| Pathway | REACTOME_SIGNALING_BY_WNT | 1.06e-03 | 330 | 20 | 4 | M7847 | |
| Pathway | REACTOME_EVASION_BY_RSV_OF_HOST_INTERFERON_RESPONSES | 1.11e-03 | 35 | 20 | 2 | M48246 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS | 1.30e-03 | 38 | 20 | 2 | M27757 | |
| Pathway | REACTOME_HSF1_DEPENDENT_TRANSACTIVATION | 1.30e-03 | 38 | 20 | 2 | M27255 | |
| Pathway | REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT | 1.37e-03 | 158 | 20 | 3 | MM14791 | |
| Pathway | REACTOME_NGF_STIMULATED_TRANSCRIPTION | 1.37e-03 | 39 | 20 | 2 | M29793 | |
| Pathway | WP_SUDDEN_INFANT_DEATH_SYNDROME_SIDS_SUSCEPTIBILITY_PATHWAYS | 1.39e-03 | 159 | 20 | 3 | M39373 | |
| Pathway | PID_FOXM1_PATHWAY | 1.44e-03 | 40 | 20 | 2 | M176 | |
| Pathway | PID_IFNG_PATHWAY | 1.44e-03 | 40 | 20 | 2 | M161 | |
| Pathway | REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT | 1.59e-03 | 42 | 20 | 2 | M17541 | |
| Pathway | REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX | 1.59e-03 | 42 | 20 | 2 | M27272 | |
| Pathway | PID_HNF3A_PATHWAY | 1.75e-03 | 44 | 20 | 2 | M285 | |
| Pathway | REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS | 1.75e-03 | 44 | 20 | 2 | M27295 | |
| Pathway | KEGG_NOTCH_SIGNALING_PATHWAY | 1.99e-03 | 47 | 20 | 2 | M7946 | |
| Pathway | PID_HES_HEY_PATHWAY | 2.07e-03 | 48 | 20 | 2 | M288 | |
| Pathway | REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 2.07e-03 | 48 | 20 | 2 | M611 | |
| Pathway | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION | 2.15e-03 | 1387 | 20 | 7 | M734 | |
| Pathway | REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_CELL_CYCLE_GENES | 2.16e-03 | 49 | 20 | 2 | M27614 | |
| Pathway | PID_FOXO_PATHWAY | 2.16e-03 | 49 | 20 | 2 | M136 | |
| Pathway | REACTOME_HEME_SIGNALING | 2.16e-03 | 49 | 20 | 2 | M41832 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH3 | 2.16e-03 | 49 | 20 | 2 | M618 | |
| Pathway | BIOCARTA_PPARA_PATHWAY | 2.43e-03 | 52 | 20 | 2 | M2404 | |
| Pathway | PID_NFAT_3PATHWAY | 2.52e-03 | 53 | 20 | 2 | M113 | |
| Pathway | PID_AR_TF_PATHWAY | 2.52e-03 | 53 | 20 | 2 | M151 | |
| Pathway | WP_TGFBETA_SIGNALING_PATHWAY | 2.52e-03 | 53 | 20 | 2 | MM15880 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING | 2.71e-03 | 55 | 20 | 2 | M39351 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_ACTIVATION_OF_MITOCHONDRIAL_BIOGENESIS | 2.71e-03 | 55 | 20 | 2 | M27145 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER | 3.01e-03 | 58 | 20 | 2 | M29616 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING_IN_SKELETAL_DYSPLASIAS | 3.12e-03 | 59 | 20 | 2 | M39886 | |
| Pathway | PID_P53_REGULATION_PATHWAY | 3.12e-03 | 59 | 20 | 2 | M261 | |
| Pathway | WP_SIDS_SUSCEPTIBILITY_PATHWAYS | 3.12e-03 | 59 | 20 | 2 | MM15838 | |
| Pathway | REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION | 3.33e-03 | 61 | 20 | 2 | M152 | |
| Pathway | REACTOME_CYTOSOLIC_SENSORS_OF_PATHOGEN_ASSOCIATED_DNA | 3.66e-03 | 64 | 20 | 2 | M27046 | |
| Pathway | WP_HISTONE_MODIFICATIONS | 3.77e-03 | 65 | 20 | 2 | M39374 | |
| Pathway | PID_RB_1PATHWAY | 3.77e-03 | 65 | 20 | 2 | M279 | |
| Pathway | PID_HIF1_TFPATHWAY | 3.88e-03 | 66 | 20 | 2 | M255 | |
| Pathway | PID_HDAC_CLASSI_PATHWAY | 3.88e-03 | 66 | 20 | 2 | M101 | |
| Pubmed | Identification of cancer/testis-antigen genes by massively parallel signature sequencing. | 3.91e-10 | 15 | 27 | 4 | 15905330 | |
| Pubmed | 1.67e-09 | 4 | 27 | 3 | 28398509 | ||
| Pubmed | Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation. | 4.57e-08 | 457 | 27 | 7 | 32344865 | |
| Pubmed | 1.11e-07 | 57 | 27 | 4 | 18022353 | ||
| Pubmed | 1.59e-07 | 549 | 27 | 7 | 38280479 | ||
| Pubmed | 2.01e-07 | 66 | 27 | 4 | 23275444 | ||
| Pubmed | Cohesin regulates tissue-specific expression by stabilizing highly occupied cis-regulatory modules. | 2.32e-07 | 16 | 27 | 3 | 22780989 | |
| Pubmed | Interaction network of human early embryonic transcription factors. | 2.51e-07 | 351 | 27 | 6 | 38297188 | |
| Pubmed | 4.37e-07 | 638 | 27 | 7 | 31182584 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 27881875 | ||
| Pubmed | Expression of the nuclear coactivators CBP and p300 in developing craniofacial tissue. | 5.80e-07 | 2 | 27 | 2 | 11963968 | |
| Pubmed | Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. | 5.80e-07 | 2 | 27 | 2 | 34845315 | |
| Pubmed | p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. | 5.80e-07 | 2 | 27 | 2 | 34813504 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 19729597 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 15860545 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 9528808 | ||
| Pubmed | Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines. | 5.80e-07 | 2 | 27 | 2 | 12696060 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 29460469 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 20301699 | ||
| Pubmed | Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer. | 5.80e-07 | 2 | 27 | 2 | 24551300 | |
| Pubmed | CBP Is Required for Establishing Adaptive Gene Programs in the Adult Mouse Brain. | 5.80e-07 | 2 | 27 | 2 | 36109165 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 24639469 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 37816914 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 12242694 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 33911074 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 9018065 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 24648406 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 30135524 | ||
| Pubmed | Binding of p300/CBP co-activators by polyoma large T antigen. | 5.80e-07 | 2 | 27 | 2 | 11438528 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 10918613 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 31182547 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 35502657 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 39287984 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 30635043 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 31898871 | ||
| Pubmed | Distribution of co-activators CBP and p300 during mouse oocyte and embryo development. | 5.80e-07 | 2 | 27 | 2 | 16596650 | |
| Pubmed | Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations. | 5.80e-07 | 2 | 27 | 2 | 27648933 | |
| Pubmed | Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity. | 5.80e-07 | 2 | 27 | 2 | 30888860 | |
| Pubmed | Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. | 5.80e-07 | 2 | 27 | 2 | 27881443 | |
| Pubmed | The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation. | 5.80e-07 | 2 | 27 | 2 | 29217654 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 19272189 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 10610021 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 20682801 | ||
| Pubmed | Emerging roles of p300/CBP in autophagy and autophagy-related human disorders. | 5.80e-07 | 2 | 27 | 2 | 37314181 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 20717166 | ||
| Pubmed | Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. | 5.80e-07 | 2 | 27 | 2 | 12397173 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 10049825 | ||
| Pubmed | CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. | 5.80e-07 | 2 | 27 | 2 | 15641773 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 38811552 | ||
| Pubmed | Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. | 5.80e-07 | 2 | 27 | 2 | 32690000 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 9733868 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 30953353 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 21803292 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 33767438 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 9811832 | ||
| Pubmed | CBP/p300 acetyltransferase activity in hematologic malignancies. | 5.80e-07 | 2 | 27 | 2 | 27380996 | |
| Pubmed | CREBBP and p300 lysine acetyl transferases in the DNA damage response. | 5.80e-07 | 2 | 27 | 2 | 29170789 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 24089570 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 25893291 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 11559821 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 21555743 | ||
| Pubmed | Rubinstein-Taybi syndrome in Chinese population with four novel mutations. | 5.80e-07 | 2 | 27 | 2 | 33063428 | |
| Pubmed | CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells. | 5.80e-07 | 2 | 27 | 2 | 12646247 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 34506759 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 22177454 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 15371335 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 15706485 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 32576962 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 19822209 | ||
| Pubmed | AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. | 5.80e-07 | 2 | 27 | 2 | 39266679 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 24522976 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 22303793 | ||
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 11867645 | ||
| Pubmed | CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement. | 5.80e-07 | 2 | 27 | 2 | 21847097 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 34732714 | ||
| Pubmed | Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. | 5.80e-07 | 2 | 27 | 2 | 34019788 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 12433930 | ||
| Pubmed | Composite co-activator ARC mediates chromatin-directed transcriptional activation. | 7.31e-07 | 23 | 27 | 3 | 10235267 | |
| Pubmed | 7.66e-07 | 425 | 27 | 6 | 24999758 | ||
| Pubmed | 7.80e-07 | 1429 | 27 | 9 | 35140242 | ||
| Pubmed | 1.03e-06 | 99 | 27 | 4 | 34161765 | ||
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 15598887 | ||
| Pubmed | Dendrite development regulated by CREST, a calcium-regulated transcriptional activator. | 1.74e-06 | 3 | 27 | 2 | 14716005 | |
| Pubmed | The acetate/ACSS2 switch regulates HIF-2 stress signaling in the tumor cell microenvironment. | 1.74e-06 | 3 | 27 | 2 | 25689462 | |
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 18070920 | ||
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 11973335 | ||
| Pubmed | The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression. | 1.74e-06 | 3 | 27 | 2 | 21967847 | |
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 9194564 | ||
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 15171256 | ||
| Pubmed | p300/CBP acts as a coactivator of the cone-rod homeobox transcription factor. | 1.74e-06 | 3 | 27 | 2 | 10708567 | |
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 16428436 | ||
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 22523253 | ||
| Pubmed | Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. | 1.74e-06 | 3 | 27 | 2 | 11823864 | |
| Pubmed | CBP and p300 are essential for renin cell identity and morphological integrity of the kidney. | 1.74e-06 | 3 | 27 | 2 | 19252086 | |
| Pubmed | An essential role for p300/CBP in the cellular response to hypoxia. | 1.74e-06 | 3 | 27 | 2 | 8917528 | |
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 19948376 | ||
| Pubmed | E2A and CBP/p300 act in synergy to promote chromatin accessibility of the immunoglobulin κ locus. | 1.74e-06 | 3 | 27 | 2 | 22544934 | |
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 27903646 | ||
| Pubmed | Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. | 1.74e-06 | 3 | 27 | 2 | 10673499 | |
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 12748286 | ||
| Interaction | GCM1 interactions | 2.34e-08 | 68 | 26 | 5 | int:GCM1 | |
| Interaction | EGR2 interactions | 6.84e-08 | 171 | 26 | 6 | int:EGR2 | |
| Interaction | GSC interactions | 8.17e-08 | 87 | 26 | 5 | int:GSC | |
| Interaction | MYOD1 interactions | 1.44e-07 | 194 | 26 | 6 | int:MYOD1 | |
| Interaction | PAX8 interactions | 2.78e-07 | 111 | 26 | 5 | int:PAX8 | |
| Interaction | ERG interactions | 3.28e-07 | 223 | 26 | 6 | int:ERG | |
| Interaction | TBXT interactions | 3.46e-07 | 116 | 26 | 5 | int:TBXT | |
| Interaction | CRX interactions | 7.04e-07 | 254 | 26 | 6 | int:CRX | |
| Interaction | NUP35 interactions | 8.08e-07 | 424 | 26 | 7 | int:NUP35 | |
| Interaction | SP7 interactions | 2.00e-06 | 304 | 26 | 6 | int:SP7 | |
| Interaction | HNF1B interactions | 3.96e-06 | 190 | 26 | 5 | int:HNF1B | |
| Interaction | KLF5 interactions | 4.49e-06 | 195 | 26 | 5 | int:KLF5 | |
| Interaction | GATA2 interactions | 4.96e-06 | 199 | 26 | 5 | int:GATA2 | |
| Interaction | FEV interactions | 5.47e-06 | 203 | 26 | 5 | int:FEV | |
| Interaction | FOXI1 interactions | 5.63e-06 | 92 | 26 | 4 | int:FOXI1 | |
| Interaction | SOX9 interactions | 6.95e-06 | 97 | 26 | 4 | int:SOX9 | |
| Interaction | TBR1 interactions | 1.27e-05 | 113 | 26 | 4 | int:TBR1 | |
| Interaction | PAX7 interactions | 1.84e-05 | 124 | 26 | 4 | int:PAX7 | |
| Interaction | PAX9 interactions | 2.21e-05 | 130 | 26 | 4 | int:PAX9 | |
| Interaction | CXXC1 interactions | 2.35e-05 | 132 | 26 | 4 | int:CXXC1 | |
| Interaction | AR interactions | 2.37e-05 | 992 | 26 | 8 | int:AR | |
| Interaction | KLF15 interactions | 3.06e-05 | 290 | 26 | 5 | int:KLF15 | |
| Interaction | PYGO2 interactions | 3.17e-05 | 48 | 26 | 3 | int:PYGO2 | |
| Interaction | FOS interactions | 4.34e-05 | 312 | 26 | 5 | int:FOS | |
| Interaction | SOX2 interactions | 4.39e-05 | 1422 | 26 | 9 | int:SOX2 | |
| Interaction | KLF4 interactions | 4.99e-05 | 160 | 26 | 4 | int:KLF4 | |
| Interaction | HOXB3 interactions | 5.73e-05 | 9 | 26 | 2 | int:HOXB3 | |
| Interaction | ARGFX interactions | 5.73e-05 | 9 | 26 | 2 | int:ARGFX | |
| Interaction | SSBP4 interactions | 5.91e-05 | 59 | 26 | 3 | int:SSBP4 | |
| Interaction | SETD1A interactions | 6.32e-05 | 170 | 26 | 4 | int:SETD1A | |
| Interaction | EPAS1 interactions | 6.77e-05 | 173 | 26 | 4 | int:EPAS1 | |
| Interaction | TLX1 interactions | 7.07e-05 | 175 | 26 | 4 | int:TLX1 | |
| Interaction | GATA3 interactions | 9.15e-05 | 187 | 26 | 4 | int:GATA3 | |
| Interaction | PAX6 interactions | 9.24e-05 | 366 | 26 | 5 | int:PAX6 | |
| Interaction | ETV4 interactions | 9.44e-05 | 69 | 26 | 3 | int:ETV4 | |
| Interaction | TLE3 interactions | 1.05e-04 | 376 | 26 | 5 | int:TLE3 | |
| Interaction | EWSR1 interactions | 1.13e-04 | 906 | 26 | 7 | int:EWSR1 | |
| Interaction | MEX3A interactions | 1.16e-04 | 384 | 26 | 5 | int:MEX3A | |
| Interaction | GPBP1 interactions | 1.21e-04 | 75 | 26 | 3 | int:GPBP1 | |
| Interaction | ASCL2 interactions | 1.24e-04 | 13 | 26 | 2 | int:ASCL2 | |
| Interaction | HNF1A interactions | 1.47e-04 | 80 | 26 | 3 | int:HNF1A | |
| Interaction | SOX7 interactions | 1.58e-04 | 82 | 26 | 3 | int:SOX7 | |
| Interaction | KLF2 interactions | 1.66e-04 | 15 | 26 | 2 | int:KLF2 | |
| Interaction | PSD2 interactions | 1.66e-04 | 15 | 26 | 2 | int:PSD2 | |
| Interaction | SP3 interactions | 1.69e-04 | 84 | 26 | 3 | int:SP3 | |
| Interaction | IRF4 interactions | 1.76e-04 | 85 | 26 | 3 | int:IRF4 | |
| Interaction | NR3C1 interactions | 1.77e-04 | 974 | 26 | 7 | int:NR3C1 | |
| Interaction | WWTR1 interactions | 1.80e-04 | 422 | 26 | 5 | int:WWTR1 | |
| Interaction | CDX2 interactions | 1.82e-04 | 86 | 26 | 3 | int:CDX2 | |
| Interaction | PPP1R13L interactions | 1.95e-04 | 88 | 26 | 3 | int:PPP1R13L | |
| Interaction | MAML2 interactions | 2.15e-04 | 17 | 26 | 2 | int:MAML2 | |
| Interaction | PABPC1 interactions | 2.17e-04 | 699 | 26 | 6 | int:PABPC1 | |
| Interaction | RERE interactions | 2.29e-04 | 93 | 26 | 3 | int:RERE | |
| Interaction | EYA4 interactions | 2.50e-04 | 243 | 26 | 4 | int:EYA4 | |
| Interaction | GLI3 interactions | 2.67e-04 | 98 | 26 | 3 | int:GLI3 | |
| Interaction | NEUROG1 interactions | 2.70e-04 | 19 | 26 | 2 | int:NEUROG1 | |
| Interaction | SPIB interactions | 3.00e-04 | 20 | 26 | 2 | int:SPIB | |
| Interaction | SSBP2 interactions | 3.27e-04 | 105 | 26 | 3 | int:SSBP2 | |
| Interaction | CITED4 interactions | 3.31e-04 | 21 | 26 | 2 | int:CITED4 | |
| Interaction | HOXB4 interactions | 3.31e-04 | 21 | 26 | 2 | int:HOXB4 | |
| Interaction | PLAGL1 interactions | 3.31e-04 | 21 | 26 | 2 | int:PLAGL1 | |
| Interaction | KLF13 interactions | 3.31e-04 | 21 | 26 | 2 | int:KLF13 | |
| Interaction | YAP1 interactions | 3.62e-04 | 1095 | 26 | 7 | int:YAP1 | |
| Interaction | TOP3B interactions | 3.74e-04 | 1470 | 26 | 8 | int:TOP3B | |
| Interaction | CITED2 interactions | 3.98e-04 | 23 | 26 | 2 | int:CITED2 | |
| Interaction | HOXD10 interactions | 3.98e-04 | 23 | 26 | 2 | int:HOXD10 | |
| Interaction | HNF4A interactions | 4.00e-04 | 275 | 26 | 4 | int:HNF4A | |
| Interaction | LDB1 interactions | 4.28e-04 | 115 | 26 | 3 | int:LDB1 | |
| Interaction | TBX21 interactions | 4.34e-04 | 24 | 26 | 2 | int:TBX21 | |
| Interaction | CNTN2 interactions | 4.34e-04 | 24 | 26 | 2 | int:CNTN2 | |
| Interaction | NR6A1 interactions | 4.34e-04 | 24 | 26 | 2 | int:NR6A1 | |
| Interaction | ALX1 interactions | 4.71e-04 | 25 | 26 | 2 | int:ALX1 | |
| Interaction | TLX3 interactions | 4.95e-04 | 291 | 26 | 4 | int:TLX3 | |
| Interaction | HOXB7 interactions | 5.10e-04 | 26 | 26 | 2 | int:HOXB7 | |
| Interaction | POLR2A interactions | 5.41e-04 | 536 | 26 | 5 | int:POLR2A | |
| Interaction | FMR1 interactions | 5.41e-04 | 536 | 26 | 5 | int:FMR1 | |
| Interaction | VDR interactions | 5.72e-04 | 127 | 26 | 3 | int:VDR | |
| Interaction | PYGO1 interactions | 5.93e-04 | 28 | 26 | 2 | int:PYGO1 | |
| Interaction | FHL1 interactions | 5.98e-04 | 129 | 26 | 3 | int:FHL1 | |
| Interaction | PPARG interactions | 6.06e-04 | 307 | 26 | 4 | int:PPARG | |
| Interaction | KCNC3 interactions | 6.36e-04 | 29 | 26 | 2 | int:KCNC3 | |
| Interaction | HOXD4 interactions | 6.81e-04 | 30 | 26 | 2 | int:HOXD4 | |
| Interaction | SMG7 interactions | 6.99e-04 | 319 | 26 | 4 | int:SMG7 | |
| Interaction | LRRTM4 interactions | 7.27e-04 | 31 | 26 | 2 | int:LRRTM4 | |
| Interaction | IZUMO1 interactions | 7.27e-04 | 31 | 26 | 2 | int:IZUMO1 | |
| Interaction | CRTC1 interactions | 7.27e-04 | 31 | 26 | 2 | int:CRTC1 | |
| Interaction | GTF2B interactions | 7.75e-04 | 141 | 26 | 3 | int:GTF2B | |
| Interaction | NEUROD1 interactions | 7.75e-04 | 32 | 26 | 2 | int:NEUROD1 | |
| Interaction | CEBPA interactions | 7.85e-04 | 1245 | 26 | 7 | int:CEBPA | |
| Interaction | TLX2 interactions | 7.91e-04 | 142 | 26 | 3 | int:TLX2 | |
| Interaction | NFIB interactions | 7.91e-04 | 142 | 26 | 3 | int:NFIB | |
| Interaction | RPS6KA5 interactions | 8.23e-04 | 144 | 26 | 3 | int:RPS6KA5 | |
| Interaction | TRERF1 interactions | 8.25e-04 | 33 | 26 | 2 | int:TRERF1 | |
| Interaction | NCOA6 interactions | 8.40e-04 | 145 | 26 | 3 | int:NCOA6 | |
| Interaction | C3orf62 interactions | 9.28e-04 | 35 | 26 | 2 | int:C3orf62 | |
| Interaction | HSF1 interactions | 9.63e-04 | 609 | 26 | 5 | int:HSF1 | |
| Interaction | E2F5 interactions | 9.81e-04 | 36 | 26 | 2 | int:E2F5 | |
| Interaction | HOXB2 interactions | 9.81e-04 | 36 | 26 | 2 | int:HOXB2 | |
| Interaction | CITED1 interactions | 1.04e-03 | 37 | 26 | 2 | int:CITED1 | |
| Interaction | KLF1 interactions | 1.04e-03 | 37 | 26 | 2 | int:KLF1 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chrXq26 | 3.05e-06 | 171 | 27 | 4 | chrXq26 | |
| Cytoband | Xq26.3 | 7.19e-04 | 67 | 27 | 2 | Xq26.3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr14q24 | 6.17e-03 | 200 | 27 | 2 | chr14q24 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 7.52e-05 | 17 | 14 | 2 | 486 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 8.46e-05 | 18 | 14 | 2 | 91 | |
| GeneFamily | Zinc fingers C2H2-type|Lysine methyltransferases|PR/SET domain family | 3.08e-04 | 34 | 14 | 2 | 487 | |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C0_MYOFIBROBLAST_1_CELL | 7.37e-07 | 69 | 27 | 4 | M45681 | |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C0_MYOFIBROBLAST_2_CELL | 3.83e-06 | 104 | 27 | 4 | M45682 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN | 6.67e-06 | 467 | 27 | 6 | M1347 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN | 8.18e-06 | 484 | 27 | 6 | MM999 | |
| Coexpression | IWANAGA_CARCINOGENESIS_BY_KRAS_UP | 3.12e-05 | 177 | 27 | 4 | M9118 | |
| Coexpression | GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP | 3.34e-05 | 180 | 27 | 4 | M8239 | |
| Coexpression | IWANAGA_CARCINOGENESIS_BY_KRAS_UP | 4.29e-05 | 192 | 27 | 4 | MM752 | |
| ToppCell | PND01-03-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 5.12e-06 | 191 | 27 | 4 | e7c605b56934d1383237c1f946dbccef25d91368 | |
| ToppCell | PND01-03-samps-Mesenchymal-Matrix_fibroblast|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 5.67e-06 | 196 | 27 | 4 | 54f4cf778f95a9ff662e5c7520916a25e605bf95 | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 5.78e-06 | 197 | 27 | 4 | 1485933986921ff45669d9b7501c8d17050b3e97 | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 5.90e-06 | 198 | 27 | 4 | 285f729140b1df029c24f6ca1d2438470ac51794 | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 5.90e-06 | 198 | 27 | 4 | aa80315395cb5dffc25927c8a77cd2037aea8772 | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 6.02e-06 | 199 | 27 | 4 | 5b140ac88ebc25ce397ae577e48f3e271faf46e7 | |
| ToppCell | E15.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.08e-04 | 154 | 27 | 3 | e65e4636646164610f33f7bbac0d879a3ea55986 | |
| ToppCell | wk_15-18-Mesenchymal-Myofibro_&_SMC-Myofibro_2|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 1.15e-04 | 157 | 27 | 3 | b9d04ee417c0d8ea0801d10f1c54e138587009fd | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Mes)|kidney / Disease (COVID-19 only), tissue and cell type | 1.19e-04 | 159 | 27 | 3 | 5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d | |
| ToppCell | P07-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.24e-04 | 161 | 27 | 3 | b19f82dd98a3064581793711bb70373f18abecd9 | |
| ToppCell | wk_08-11-Mesenchymal-Myofibro_&_SMC-Myofibro_2|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 1.45e-04 | 170 | 27 | 3 | fefb07a7e308b620f946b9ff2b01e1796446fe38 | |
| ToppCell | Children_(3_yrs)-Epithelial-club_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.72e-04 | 180 | 27 | 3 | b509c7d6bdfba672065fb722874bdc68de72ba1c | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.72e-04 | 180 | 27 | 3 | b798a3fa2dd15b68aa4267f665559527043dcc07 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.77e-04 | 182 | 27 | 3 | 17ed11a7ea366dd3106400511d5e628d3f1a9c3e | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.83e-04 | 184 | 27 | 3 | ab2f06906fc7a9931dfa0864ef506832b07fb93e | |
| ToppCell | COVID-19-Epithelial_cells-Airway_club|COVID-19 / group, cell type (main and fine annotations) | 1.86e-04 | 185 | 27 | 3 | cfe6fd73d817e173fe803bc1683c291d9bcb8608 | |
| ToppCell | P03|World / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.86e-04 | 185 | 27 | 3 | a07dbe1f76e40734a28826423a5cc64b8e56af5e | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.89e-04 | 186 | 27 | 3 | e83718fabb057100835d3357df407f283d23fe16 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.89e-04 | 186 | 27 | 3 | f73cb91e74a806858650ae97f543fc779ba4cff8 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-Mono-Mono_anti-infl|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.89e-04 | 186 | 27 | 3 | 8694ca16c9780729f4fba67ba20e35745f1eb4e9 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.92e-04 | 187 | 27 | 3 | 201ff693e4756ee3e44762885b3a303a77eb535b | |
| ToppCell | pdx-Tumor_cells-T5|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 1.92e-04 | 187 | 27 | 3 | 7e376831a11ee72ed87abcdac631ca46ae29c250 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.95e-04 | 188 | 27 | 3 | 4bdf8d49af0e9da349b16e3f012e1b0eec04cc4f | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.95e-04 | 188 | 27 | 3 | 6164d467b612767ceba15de34176bcc8e8c36ab8 | |
| ToppCell | PND07-28-samps-Mesenchymal-Matrix_fibroblast|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 1.98e-04 | 189 | 27 | 3 | dc5164591dea45b420798b94dda211be03daa70c | |
| ToppCell | wk_15-18-Mesenchymal-Myofibro_&_SMC-Myofibro_1|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 2.01e-04 | 190 | 27 | 3 | d24af6af3271e34afab744352afd28be8a7cc5c3 | |
| ToppCell | wk_08-11-Mesenchymal-Myofibro_&_SMC-Myofibro_1|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 2.01e-04 | 190 | 27 | 3 | 71a00f63fdd4eb4cc6f190d37e7a0417cdaafacb | |
| ToppCell | PND07-28-samps-Mesenchymal-Matrix_fibroblast-FB-3|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 2.01e-04 | 190 | 27 | 3 | 1196b8ea2c44c7c80f5ee589dd517e6a413f2077 | |
| ToppCell | PND14-Mesenchymal-Mesenchymal_structural|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.08e-04 | 192 | 27 | 3 | 25492568f9cbe097b7bb1db50d8b817c80ea87d7 | |
| ToppCell | P03-Mesenchymal-mesenchymal_fibroblast-alveolar_fibroblast_Wnt2-pa|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.08e-04 | 192 | 27 | 3 | 2802fae55683345ff94a1ecf73b6fbee4f17481e | |
| ToppCell | P07-Mesenchymal-mesenchymal_fibroblast-alveolar_fibroblast_Wnt2-pa|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.08e-04 | 192 | 27 | 3 | 0afb9dbe468e0be442c326e11c5fc0f699b32f23 | |
| ToppCell | PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.08e-04 | 192 | 27 | 3 | de9c1536d5aee86f9c62acbc54ca8fa581c00f17 | |
| ToppCell | Epithelial-club_cell|World / Lineage, Cell type, age group and donor | 2.11e-04 | 193 | 27 | 3 | 2bdd09004fa433550958ec42ba4b06271a4aaf7c | |
| ToppCell | critical-Lymphoid-NK|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.11e-04 | 193 | 27 | 3 | 6be11fef87af04ee7a3cc223882ccd4077caded9 | |
| ToppCell | wk_20-22-Mesenchymal-Myofibro_&_SMC-Myofibro_2|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 2.11e-04 | 193 | 27 | 3 | 2f203f6f0c2135acb046c9351a633c3b5b254a46 | |
| ToppCell | PND01-03-samps-Mesenchymal|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 2.14e-04 | 194 | 27 | 3 | 4f9bd0ded0dde1df885850714f29e73e992539a5 | |
| ToppCell | PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.17e-04 | 195 | 27 | 3 | 2b8ee7990267bb52b7e6ae03f509ffebf8908122 | |
| ToppCell | PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.17e-04 | 195 | 27 | 3 | 3a0cad69cfc150a27a0666f612f5294c817197d7 | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.20e-04 | 196 | 27 | 3 | 2a885eed52f9b002c7995e11e450c7e8d7ae69e6 | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.20e-04 | 196 | 27 | 3 | 14246f00c90741a5f8683f377e22e3a7c99661b9 | |
| ToppCell | Control_saline-Epithelial_alveolar-AT_2-Differentiating_AT2|Control_saline / Treatment groups by lineage, cell group, cell type | 2.24e-04 | 197 | 27 | 3 | 44a59dfb889577b3160a5b13ada1276771a00241 | |
| ToppCell | Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_pulmonary|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.24e-04 | 197 | 27 | 3 | ac4f53acb2f8a428b0f2fab3c30a34e095a1bed7 | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.24e-04 | 197 | 27 | 3 | 1638959d7aecb9fc5285eb7e4a3103ca437989e2 | |
| ToppCell | Parenchymal-NucSeq|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations | 2.27e-04 | 198 | 27 | 3 | 1996373bdccc55aac347d349bd22f6aad6d0c668 | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar-AT_2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 2.27e-04 | 198 | 27 | 3 | c4e7512f0e1d115f2be8acae6048eda8b6b640b2 | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.27e-04 | 198 | 27 | 3 | 53e9ed1b19cb26be58da0f37057caca0cdfaabeb | |
| ToppCell | Tracheal-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.27e-04 | 198 | 27 | 3 | 1e1ea54f0c234f3b6d29064c4881d8a0c0949a75 | |
| ToppCell | Fetal_29-31_weeks-Epithelial-club_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 2.27e-04 | 198 | 27 | 3 | 5fc25b008a4d8d6bec83923a16f64dd9e1ff1f2d | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 2.31e-04 | 199 | 27 | 3 | 121de4e02585de3a3010398387c523bacf8ce546 | |
| ToppCell | Macroglial-Oligodendrocytes|Macroglial / cells hierarchy compared to all cells using T-Statistic | 2.34e-04 | 200 | 27 | 3 | 4dbac2f2587e87ca5a0622f50439bb5447e93c7f | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 2.34e-04 | 200 | 27 | 3 | e8db082aa4d0597500e4f16a5c0ea3e62c6c59ae | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW10-Neuronal-Cortical_neuron|GW10 / Sample Type, Dataset, Time_group, and Cell type. | 2.34e-04 | 200 | 27 | 3 | 458fb0f40c1720f1cacedf78c40bd059692bfc62 | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 2.34e-04 | 200 | 27 | 3 | c89f3cb36bb14c476d6a392bfd3ded1c8feecfeb | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN----L1-6|Macroglial / cells hierarchy compared to all cells using T-Statistic | 2.34e-04 | 200 | 27 | 3 | 272909f4354f3ae22e2b2f8f35970e6b0e92cfe2 | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN--|Macroglial / cells hierarchy compared to all cells using T-Statistic | 2.34e-04 | 200 | 27 | 3 | 26b989e30bbbaf30904ced03f6aae3dea25c732c | |
| ToppCell | MS-IIF|MS / Disease, condition lineage and cell class | 2.34e-04 | 200 | 27 | 3 | 221f59edcfc18baece13184c2552d26022228146 | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN---|Macroglial / cells hierarchy compared to all cells using T-Statistic | 2.34e-04 | 200 | 27 | 3 | 1314664c1721e9ecb1e2c3482a039044b0fe50a9 | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN|Macroglial / cells hierarchy compared to all cells using T-Statistic | 2.34e-04 | 200 | 27 | 3 | 5f75a9b8bcd49d9bbb1e9ce2de730eaec96369ca | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / Treatment groups by lineage, cell group, cell type | 2.34e-04 | 200 | 27 | 3 | 2dadf317a42a7e27cc1fac74f91b806c93a57108 | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN-|Macroglial / cells hierarchy compared to all cells using T-Statistic | 2.34e-04 | 200 | 27 | 3 | 8b229f095fc113aecfc94b64862a9e0fdcc363ce | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 2.34e-04 | 200 | 27 | 3 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-2_Progenitor-AT2_Progenitor|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 2.34e-04 | 200 | 27 | 3 | b6cfe5e205ade8bcb75555564f3f57f03f6e40be | |
| Drug | Midodrine hydrochloride [3092-17-9]; Up 200; 13.8uM; PC3; HT_HG-U133A | 2.02e-06 | 195 | 25 | 5 | 2087_UP | |
| Drug | 3,4-dimethoxy-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide | 1.16e-05 | 5 | 25 | 2 | ctd:C575894 | |
| Drug | NSC289491 | 3.23e-05 | 8 | 25 | 2 | CID000002693 | |
| Drug | AC1NUW7G | 4.04e-05 | 61 | 25 | 3 | CID005462208 | |
| Drug | Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A | 4.20e-05 | 180 | 25 | 4 | 4541_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A | 4.20e-05 | 180 | 25 | 4 | 6886_DN | |
| Drug | CP-690334-01 [459212-38-5]; Up 200; 10uM; PC3; HT_HG-U133A | 4.97e-05 | 188 | 25 | 4 | 3823_UP | |
| Drug | 5707885; Down 200; 50uM; PC3; HT_HG-U133A | 5.29e-05 | 191 | 25 | 4 | 6390_DN | |
| Drug | paclitaxel; Down 200; 0.1uM; MCF7; HG-U133A | 5.62e-05 | 194 | 25 | 4 | 640_DN | |
| Drug | (S)-(-)-Cycloserine [339-72-0]; Up 200; 39.2uM; PC3; HT_HG-U133A | 5.73e-05 | 195 | 25 | 4 | 3789_UP | |
| Drug | Tetrandrine [518-34-3]; Down 200; 6.4uM; MCF7; HT_HG-U133A | 5.73e-05 | 195 | 25 | 4 | 6082_DN | |
| Drug | Merbromin [129-16-8]; Up 200; 5uM; PC3; HT_HG-U133A | 5.85e-05 | 196 | 25 | 4 | 3700_UP | |
| Drug | Hydroxytacrine maleate (R,S) [118909-22-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 5.96e-05 | 197 | 25 | 4 | 3292_UP | |
| Drug | 0225151-0000 [351320-15-5]; Down 200; 10uM; PC3; HT_HG-U133A | 5.96e-05 | 197 | 25 | 4 | 6389_DN | |
| Drug | CP-320650-01 [172079-28-6]; Down 200; 10uM; PC3; HT_HG-U133A | 5.96e-05 | 197 | 25 | 4 | 4557_DN | |
| Drug | Levonordefrin [829-74-3]; Down 200; 21.8uM; MCF7; HT_HG-U133A | 6.08e-05 | 198 | 25 | 4 | 3450_DN | |
| Drug | Betazole hydrochloride; Down 200; 27uM; PC3; HT_HG-U133A | 6.08e-05 | 198 | 25 | 4 | 1812_DN | |
| Drug | Pheniramine maleate [132-20-7]; Up 200; 11.2uM; PC3; HG-U133A | 6.08e-05 | 198 | 25 | 4 | 1910_UP | |
| Drug | Naloxone hydrochloride [357-08-4]; Up 200; 11uM; PC3; HG-U133A | 6.08e-05 | 198 | 25 | 4 | 1924_UP | |
| Drug | CP-319743 [172078-87-4]; Up 200; 10uM; MCF7; HT_HG-U133A | 6.20e-05 | 199 | 25 | 4 | 7532_UP | |
| Drug | alpha-Santonin [481-06-1]; Down 200; 16.2uM; PC3; HT_HG-U133A | 6.20e-05 | 199 | 25 | 4 | 4531_DN | |
| Disease | Menke-Hennekam syndrome | 5.81e-07 | 2 | 23 | 2 | cv:C5681632 | |
| Disease | Rubinstein-Taybi syndrome (implicated_via_orthology) | 5.81e-07 | 2 | 23 | 2 | DOID:1933 (implicated_via_orthology) | |
| Disease | Rubinstein-Taybi syndrome | 5.81e-07 | 2 | 23 | 2 | cv:C0035934 | |
| Disease | RUBINSTEIN-TAYBI SYNDROME 1 | 5.81e-07 | 2 | 23 | 2 | C4551859 | |
| Disease | Rubinstein-Taybi syndrome (is_implicated_in) | 5.81e-07 | 2 | 23 | 2 | DOID:1933 (is_implicated_in) | |
| Disease | RUBINSTEIN-TAYBI SYNDROME 1 | 5.81e-07 | 2 | 23 | 2 | 180849 | |
| Disease | Rubinstein-Taybi syndrome due to CREBBP mutations | 5.81e-07 | 2 | 23 | 2 | cv:C4551859 | |
| Disease | Rubinstein-Taybi Syndrome | 5.81e-07 | 2 | 23 | 2 | C0035934 | |
| Disease | Adenoid Cystic Carcinoma | 1.05e-06 | 100 | 23 | 4 | C0010606 | |
| Disease | Carcinoma, Transitional Cell | 4.33e-06 | 41 | 23 | 3 | C0007138 | |
| Disease | Leukemia, Myelocytic, Acute | 9.26e-06 | 173 | 23 | 4 | C0023467 | |
| Disease | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1.45e-05 | 61 | 23 | 3 | C1961102 | |
| Disease | forced expiratory volume | 2.45e-05 | 789 | 23 | 6 | EFO_0004314 | |
| Disease | Neurodevelopmental Disorders | 5.13e-05 | 93 | 23 | 3 | C1535926 | |
| Disease | Squamous cell carcinoma of esophagus | 5.46e-05 | 95 | 23 | 3 | C0279626 | |
| Disease | decreased susceptibility to hepatitis C infection | 6.93e-05 | 16 | 23 | 2 | EFO_0010101 | |
| Disease | bone mineral content measurement | 1.39e-04 | 130 | 23 | 3 | EFO_0007621 | |
| Disease | Bladder Neoplasm | 1.73e-04 | 140 | 23 | 3 | C0005695 | |
| Disease | Malignant neoplasm of urinary bladder | 1.76e-04 | 141 | 23 | 3 | C0005684 | |
| Disease | Sezary Syndrome | 2.02e-04 | 27 | 23 | 2 | C0036920 | |
| Disease | coronary aneurysm | 3.40e-04 | 35 | 23 | 2 | EFO_1000881 | |
| Disease | lung adenocarcinoma (is_implicated_in) | 6.68e-04 | 49 | 23 | 2 | DOID:3910 (is_implicated_in) | |
| Disease | ghrelin measurement | 6.68e-04 | 49 | 23 | 2 | EFO_0600001 | |
| Disease | Small cell carcinoma of lung | 8.11e-04 | 54 | 23 | 2 | C0149925 | |
| Disease | Diffuse Large B-Cell Lymphoma | 8.42e-04 | 55 | 23 | 2 | C0079744 | |
| Disease | urate measurement, spine bone mineral density | 9.36e-04 | 58 | 23 | 2 | EFO_0004531, EFO_0007701 | |
| Disease | fish consumption measurement | 1.14e-03 | 64 | 23 | 2 | EFO_0010139 | |
| Disease | Prostatic Neoplasms | 1.21e-03 | 616 | 23 | 4 | C0033578 | |
| Disease | Malignant neoplasm of prostate | 1.21e-03 | 616 | 23 | 4 | C0376358 | |
| Disease | electroencephalogram measurement | 1.52e-03 | 74 | 23 | 2 | EFO_0004357 | |
| Disease | smoking status measurement | 1.73e-03 | 1160 | 23 | 5 | EFO_0006527 | |
| Disease | Colorectal Carcinoma | 1.96e-03 | 702 | 23 | 4 | C0009402 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| KKAVPGGGMPNMGQQ | 291 | Q09472 | |
| PPPKNNMEGLNVMGK | 676 | O43506 | |
| MKQQIGSPGQPNPMS | 2301 | Q92793 | |
| KDGMMQKPGSNAPVG | 81 | P0DMU8 | |
| KDGMMQKPGSNAPVG | 81 | P0DMV0 | |
| PMEGMASNQQKALPP | 856 | Q68DA7 | |
| VEKGSAQMDPPQMGP | 601 | Q13127 | |
| GINKVMAQNNLGMPP | 3106 | Q8NEZ4 | |
| QNCPKMMEVGAKPAP | 31 | P13196 | |
| KDGMMQKPGSNAPVG | 81 | P0DMU9 | |
| EKQKGMMRPNASQPG | 1096 | Q5JU85 | |
| GMVPKLPAGKMNNRD | 1491 | Q9Y4C0 | |
| NEVEKQMNMSPPPGN | 141 | Q86U42 | |
| KSMQNPPGPVKLVME | 2786 | Q8TD57 | |
| NNIKDAMPKMQIGAP | 71 | Q14435 | |
| DGPQKKPEGPIQAMM | 396 | O00512 | |
| GPQKMLMPSQFPNQG | 831 | Q86UU0 | |
| KITHKNQAPMLMGPP | 771 | Q9Y6T7 | |
| KDGMMQKPGSNAPVG | 81 | P0DMU7 | |
| NGEPKGQPMLKDVML | 756 | P23468 | |
| MAQAGQPGKMPSGIK | 241 | Q96G25 | |
| PEAMKPAPNNQKSML | 411 | Q8IVL1 | |
| MNKARQPPPGVMPKG | 681 | A5YKK6 | |
| PPPTIMQQNKKGDMT | 1506 | Q9HBL0 | |
| PGMQPLEMVKPQSGS | 2026 | Q5JSZ5 | |
| MLQMLQPGPKLNPGV | 241 | Q96DC7 | |
| MKQLQPQPPPKMGDF | 1 | Q9BYW2 |